Praluent (Alirocumab) and Muscle Preservation: What Women Need to Know

What Alirocumab Actually Does to Muscle Tissue

Alirocumab does not cause muscle damage. That single fact is the starting point for understanding why it matters for women managing cardiovascular risk who have already struggled with statin-related muscle pain.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that degrades LDL receptors on liver cells. By binding and blocking PCSK9 with a monoclonal antibody, alirocumab allows more LDL receptors to remain active on the liver surface, pulling more LDL-cholesterol out of circulation. The mechanism is entirely hepatic. There is no known PCSK9-receptor pathway in skeletal muscle, which is precisely why the drug's prescribing information lists myalgia rates comparable to placebo.

Statins, by contrast, work by inhibiting HMG-CoA reductase in multiple tissues, including muscle cells, reducing coenzyme Q10 synthesis and possibly impairing mitochondrial function in myocytes. That dual-site activity is what produces myopathy in susceptible patients.

The Statin-Myopathy Problem Is Bigger in Women

Statin-associated muscle symptoms (SAMS) affect women disproportionately. A meta-analysis across 135,000 statin-treated patients found that women reported myalgia at rates roughly 30% higher than men on equivalent doses. One pooled analysis estimated that up to 29% of women on high-intensity statins report clinically meaningful muscle symptoms severe enough to affect daily function, compared with 19 to 21% of men.

The reasons are likely multifactorial: women generally have lower lean muscle mass relative to total body weight, meaning weight-based dosing can produce higher drug concentrations per unit of muscle tissue. Sex-based pharmacokinetic differences in CYP450 enzyme activity also play a role, though the specific statin and its metabolism pathway matter.

How Menopause Changes Muscle Vulnerability

Estrogen has direct anabolic effects on skeletal muscle. It supports satellite cell activation, reduces inflammatory cytokine signaling in muscle, and partly governs mitochondrial density in myocytes. When estrogen falls during perimenopause and after menopause, women lose this protective effect. Skeletal muscle mass declines at roughly 1 to 2% per year after menopause, and muscle fibers become more sensitive to oxidative stress.

That background muscle vulnerability amplifies statin side effects. Postmenopausal women on rosuvastatin 20 mg or atorvastatin 40 to 80 mg frequently report worsening myalgia, reduced exercise tolerance, and lower muscle strength. The JUPITER trial subgroup data suggested rosuvastatin's diabetes risk was higher in women, adding a second metabolic concern that frequently gets under-discussed in clinical practice.

Alirocumab's muscle-neutral profile makes it particularly worth discussing with your clinician if you are postmenopausal, already carrying elevated cardiovascular risk, and experiencing muscle symptoms that are limiting the physical activity you need to protect your bones and metabolic health.

ODYSSEY OUTCOMES: What the Trial Found and What It Means for Women

The ODYSSEY OUTCOMES trial, published in NEJM 2018, enrolled 18,924 patients who had experienced an acute coronary syndrome in the preceding 1 to 12 months and were already on high-intensity statin therapy. Participants were randomized to alirocumab 75 mg every 2 weeks (titrated to 150 mg if LDL remained above 50 mg/dL) or placebo.

The Primary Endpoint

Over a median follow-up of 2.8 years, alirocumab reduced the primary composite endpoint of coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, and unstable angina requiring hospitalization by 15% compared with placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; p < 0.001). All-cause mortality was also reduced (HR 0.85; 95% CI 0.73 to 0.98) in the overall cohort.

Women in ODYSSEY OUTCOMES

Women made up approximately 25% of the ODYSSEY OUTCOMES population, which is a known limitation of cardiovascular outcomes trials and one that WomanRx flags openly: the absolute event rates and relative risk reductions in women were directionally consistent with the overall result, but the trial was not powered to detect differences specifically within the female subgroup. Confidence intervals in women were wider, and clinicians should interpret that accordingly rather than assuming identical benefit.

What the trial did confirm in both sexes: alirocumab did not increase creatine kinase elevation or clinical myopathy rates above placebo. Muscle-related adverse events were rare and statistically indistinguishable from the control arm.

The Dose Titration Strategy

The adaptive dosing protocol used in ODYSSEY OUTCOMES is directly relevant to muscle-related concerns. Starting at 75 mg every 2 weeks, with titration to 150 mg only if LDL-C remained above 50 mg/dL at week 8, allowed the trial to identify a meaningful proportion of patients who achieved adequate LDL control at the lower dose. Women with lower body weight may reach target LDL at the 75 mg dose more readily, a point worth raising with your prescriber before automatically starting at the maximum dose.

Muscle Preservation Strategies When You Are on Alirocumab

Alirocumab itself is not the threat to muscle, but the broader clinical context often is. Many women starting alirocumab are either continuing a high-intensity statin alongside it or have recently discontinued a statin because of muscle symptoms. Either scenario requires a structured approach to protecting muscle.

Strategy 1: Clarify Whether the Muscle Problem Was the Statin

Before attributing myalgia to your overall lipid-lowering regimen, confirm the source. If alirocumab is being added to an existing statin, ask your clinician to recheck creatine kinase (CK) and consider whether the statin dose can be reduced. A 2022 ACC/AHA expert consensus decision pathway recommends a statin holiday of 2 to 4 weeks with CK monitoring to disentangle SAMS from other causes of muscle pain. Alirocumab can continue during a statin holiday because its mechanism is independent.

Strategy 2: Prioritize Resistance Training

Loss of lean muscle mass is a primary health threat in postmenopausal women, affecting metabolic rate, insulin sensitivity, fall risk, and fracture risk. Progressive resistance training 2 to 3 times per week has been shown to preserve lean mass and improve muscle strength in postmenopausal women, and it does not interact with PCSK9 inhibitor therapy. Because alirocumab does not impair mitochondrial function or reduce coenzyme Q10 the way statins may, women on alirocumab generally tolerate resistance exercise without the post-exercise soreness amplification that statin users frequently report.

Strategy 3: Protein Intake Calibration

Muscle protein synthesis becomes less efficient after menopause, partly due to anabolic resistance, meaning you need more dietary protein per kilogram of body weight to achieve the same muscle-building signal as a younger woman. Current evidence, including a 2023 position paper from the European Society for Clinical Nutrition and Metabolism, supports a target of 1.2 to 1.6 g of protein per kilogram of body weight per day in older adults focused on preserving muscle mass, with leucine-rich sources prioritized. Alirocumab has no known interaction with dietary protein metabolism.

Strategy 4: Vitamin D Status

Vitamin D deficiency independently worsens muscle weakness and is common in postmenopausal women. A Cochrane review of vitamin D supplementation and muscle function found improvements in muscle strength in vitamin D-deficient adults. Alirocumab does not affect vitamin D metabolism, but your overall cardiovascular-risk management plan should include a 25-OH vitamin D level and supplementation if deficient, typically to a target above 30 ng/mL.

Strategy 5: Address Any Underlying Hypothyroidism

Hypothyroidism is more common in women than men (affecting roughly 5 to 8% of adult women) and is an independent cause of myalgia that can mimic or compound statin-related muscle symptoms. Undiagnosed hypothyroidism dramatically raises rhabdomyolysis risk with statins. Before attributing muscle pain to lipid-lowering therapy at all, confirm TSH is in range. The rate of postpartum thyroiditis (up to 10% of postpartum women) and Hashimoto's disease in women of reproductive age means thyroid-related myalgia is a real differential that clinicians sometimes overlook in this population.

Who This Drug Is Right For and Who Should Reconsider

Understanding which life stages and conditions align best with alirocumab helps you have a more focused conversation with your clinician.

Women Who Are Strong Candidates

Postmenopausal women with established ASCVD or familial hypercholesterolemia. Cardiovascular risk accelerates after menopause. Women with heterozygous familial hypercholesterolemia (HeFH) and those who have had an acute coronary event are the core indication groups. If you are postmenopausal, on maximum-tolerated statin therapy, and LDL-C remains above 70 mg/dL, alirocumab is guideline-supported by the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction.

Women with statin intolerance due to myalgia. If you have tried at least two different statins at the lowest available dose and both produced intolerable muscle symptoms, that meets the clinical threshold for statin intolerance. Alirocumab monotherapy is an option in this setting, though LDL reduction will be lower without any statin co-therapy.

Women with PCOS and high cardiovascular risk. PCOS is associated with a more atherogenic lipid profile: elevated LDL, elevated triglycerides, and low HDL. Women with PCOS have a two-fold higher risk of cardiovascular events compared with age-matched controls. When lifestyle modification and metformin do not normalize LDL in a woman with PCOS who has additional ASCVD risk factors, alirocumab is a reasonable discussion point, though trial data specifically in PCOS populations are limited (see evidence gap note below).

A practical framework for life-stage candidacy:

| Life Stage | Primary Concern | Alirocumab Role | |---|---|---| | Reproductive years (18 to 40) | Familial hypercholesterolemia; must use contraception | Second-line after statin if statin intolerant | | Perimenopause (40 to 52) | Rising LDL, emerging ASCVD risk | Add-on to statin if LDL > 70 mg/dL on max statin | | Postmenopause | Accelerated ASCVD risk, statin myalgia | First consideration when statin is not tolerated | | Post-ACS (any age) | Secondary prevention | Supported by ODYSSEY OUTCOMES data |

Women Who Should Not Use Alirocumab (or Who Need Caution)

Pregnant women. Alirocumab is contraindicated in pregnancy. Full details are in the pregnancy section below.

Women with LDL <70 mg/dL who do not have established ASCVD or HeFH. Primary prevention in women at low-to-moderate risk does not have an evidence base for PCSK9 inhibitors. The cost-to-benefit calculation does not support routine use in this group.

Women with known hypersensitivity to alirocumab or any excipient. Serious allergic reactions including hypersensitivity vasculitis and eczematous reactions have been reported, though rarely. If you have had a reaction to another monoclonal antibody, discuss the allergy history with your clinician before starting.

Pregnancy, Lactation, and Contraception: Required Reading

Alirocumab is contraindicated in pregnancy.

This is not a marginal caution. Cholesterol is required for fetal development, including neural tube formation, adrenal steroidogenesis, and placental function. Inhibiting LDL clearance pathways during pregnancy could theoretically disrupt cholesterol delivery to the fetus. Animal studies at exposures exceeding the human therapeutic dose showed no direct teratogenicity with alirocumab itself, but because LDL-lowering is biologically contraindicated in pregnancy and because adequate human data do not exist, the FDA-approved prescribing information carries a contraindication for use in pregnancy.

If You Become Pregnant While on Alirocumab

Stop the drug immediately and contact your clinician. Because alirocumab is a monoclonal antibody with a half-life of approximately 17 to 20 days, it will persist in your circulation for several weeks after the last dose. ACOG recommends discontinuing all lipid-lowering therapy not deemed essential for life-threatening maternal disease during pregnancy. Report exposure to the Regeneron-Sanofi pregnancy surveillance registry (call 1-833-735-4327).

Contraception Requirements

Women of reproductive age taking alirocumab for familial hypercholesterolemia or ASCVD risk should use reliable contraception. No specific contraceptive method is contraindicated with alirocumab (unlike some anticonvulsants or rifampin, it does not induce hepatic enzymes affecting hormonal contraceptive metabolism). Combined oral contraceptives, progestin-only pills, IUDs (hormonal or copper), and implants are all pharmacologically compatible.

Lactation

It is not known whether alirocumab transfers into human breast milk. Monoclonal antibodies of similar molecular weight (approximately 148 kDa) generally transfer at very low levels into mature breast milk but may transfer more substantially into colostrum. Because neonatal gut absorption of large proteins is limited after the first few days of life, systemic exposure in a breastfeeding infant is expected to be minimal, but this has not been studied. LactMed from the National Institutes of Health lists alirocumab as having insufficient data. Given the lack of evidence and the availability of alternative approaches for managing maternal lipid levels postpartum, most clinicians advise against use during breastfeeding. A shared decision with your clinician should account for the duration of breastfeeding you plan and the severity of your cardiovascular risk.

Evidence Gaps: What We Do Not Know in Women

WomanRx is committed to naming what the data does and does not tell us.

ODYSSEY OUTCOMES enrolled only 25% women. That means the trial was underpowered to confirm the magnitude of MACE reduction specifically in women. The directional signal was consistent, but this is extrapolation to some degree.

PCOS-specific data are absent. No major trial has enrolled women with PCOS as the primary population to study alirocumab's efficacy or safety. The atherogenic dyslipidemia pattern in PCOS (elevated small dense LDL, low HDL) may respond differently than the isolated LDL elevation typically seen in HeFH, but this is theoretical.

Perimenopause-specific dosing has not been studied. Changes in body composition, hepatic enzyme activity, and inflammatory status across the menopausal transition could theoretically alter drug kinetics or LDL-lowering response, but no published pharmacokinetic sub-study has addressed this. Your prescriber should monitor LDL-C at 4 to 8 weeks after starting to confirm target attainment.

Long-term muscle mass data beyond 5 years are limited. ODYSSEY OUTCOMES ran a median of 2.8 years. Whether continued PCSK9 inhibition for a decade maintains a muscle-neutral profile in older women has not been directly studied, though mechanistic reasons to expect harm are absent.

Injection Technique and Practical Use

Alirocumab comes as a prefilled pen or syringe. The recommended injection sites are the abdomen (at least 2 inches from the navel), thigh, or upper arm. Rotate sites to reduce local reactions, which are the most common side effect: local injection site reactions occur in approximately 7% of alirocumab users, compared with 5% with placebo.

Store pens in the refrigerator. Allow each pen to reach room temperature for 30 to 40 minutes before injection to reduce injection-site discomfort. If a dose is missed and the next scheduled dose is more than 7 days away, inject as soon as you remember. If fewer than 7 days remain until the next scheduled dose, skip the missed dose and resume the regular schedule.

Monitor LDL-C at 4 to 8 weeks after initiating therapy or after a dose change to confirm adequate response. The 2018 ACC/AHA cholesterol guideline recommends an LDL-C goal below 70 mg/dL for secondary prevention and below 55 mg/dL for very-high-risk patients, with alirocumab dose adjusted accordingly.

Alirocumab in Context: Where It Fits Against Other Options

Alirocumab is not the only PCSK9 inhibitor available. Evolocumab (Repatha) has a similar mechanism and comparable LDL reduction, with the FOURIER trial showing a 15% reduction in MACE. Neither drug has been compared head-to-head in a muscle-preservation-specific trial, but both share the muscle-neutral mechanistic profile.

Inclisiran (Leqvio), a newer siRNA-based approach targeting PCSK9 mRNA, achieves comparable LDL reduction with twice-yearly subcutaneous dosing after two initial loading doses. For women who find biweekly self-injection burdensome, inclisiran may offer a practical advantage, though cardiovascular outcomes data are still maturing compared with the alirocumab dataset.

Bempedoic acid (Nexletol) lowers LDL by 18 to 25% through a different pathway and is administered orally, but it requires conversion to its active form by an enzyme (ACLY) present in the liver but not in skeletal muscle, making it another muscle-safe option. The CLEAR Outcomes trial (NEJM 2023) confirmed a 13% reduction in MACE with bempedoic acid in statin-intolerant patients, including a subgroup of women, though women again represented a minority of the trial population.

For women who cannot tolerate statins and have moderate rather than very high cardiovascular risk, ezetimibe (Zetia) remains a first-step option given its favorable tolerability, oral dosing, and modest LDL reduction of 18 to 25%.

Monitoring Schedule After Starting Alirocumab

Your clinician should check the following at the intervals listed:

• LDL-C, total cholesterol, HDL-C, triglycerides: Fasting lipid panel at 4 to 8 weeks after initiation and after each dose change, then every 6 to 12 months when stable.
• CK (creatine kinase): Check at baseline, then only if new muscle symptoms develop. Routine monitoring without symptoms is not guideline-recommended.
• TSH: Baseline if not checked in the past year, given its relevance to muscle symptoms in women.
• Liver function tests: Not routinely required with PCSK9 inhibitors (unlike statins), but check if symptoms of liver dysfunction appear.
• Blood pressure and weight: Standard cardiovascular monitoring, especially in perimenopause when both can shift.
• Injection site check: Inspect sites at follow-up visits for signs of localized hypersensitivity.

If LDL-C at 8 weeks is still above your target, your clinician may increase alirocumab from 75 mg to 150 mg every 2 weeks, which is the dose titration protocol used in ODYSSEY OUTCOMES and supported by the FDA-approved prescribing information.